Archynetys Live news trend intelligence
↑ Rising Health

2026 ESC Guidelines for the management of heart failure

The 2026 ESC guidelines introduce new heart failure classifications and a Class IA recommendation for finerenone.

7sources
7articles
5velocity
+65%since first seen
13h agofirst detected

Evidence dossier

Intelligence passport

57/100 Publishable
7distinct sources shown
13velocity measurements
1language editions checked
Unsupported statements were removed before publicationbrief evidence status

Measured timeline

  1. Detected The first matching coverage entered the Archynetys cluster.
  2. Latest coverage observed Most recent article currently attached to this story cluster.
  3. Peak measured velocity The recorded velocity reached 5.
  4. Evidence threshold reached The story had enough independent coverage for an explanatory brief.

Source diversity sample: tradingview.com · EMJ · HCPLive · Deccan Herald · Pharmaceutical Technology · dicardiology.com · Oxford Academic.

How this dossier is built: methodology · AI policy · corrections.

Quick answers

What is finerenone's status in the 2026 ESC guidelines?

It received a Class IA recommendation for heart failure.

What was released alongside the new treatment recommendations?

The second universal definition of heart failure and new disease classifications.

Which medical technology company is included in the updated guidelines?

Abbott Technologies is included in the updated ESC heart failure guidelines.

The brief

According to tradingview.com, EMJ, HCPLive, Deccan Herald, Pharmaceutical Technology, dicardiology.com, and Oxford Academic, the updated framework features the second universal definition of heart failure alongside new disease and treatment subtypes. Evidence supporting SGLT2 inhibitors and finerenone has grown within the literature, culminating in a Class IA recommendation specifically for finerenone.

The updates also incorporate Abbott Technologies into the newly revised clinical documentation. Coverage does not yet specify the full operational impact on clinical workflows or the exact timeline for nationwide adoption across different healthcare jurisdictions.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (80% supported) Updated 1h ago.

Sources (7)

How fast it spread

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Topics

Heart Failure ESC Guidelines Finerenone SGLT2 Inhibitors Abbott Technologies

Related trends

Open prediction lab

Can you beat the machine?

Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.

Make a prediction →